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Src and Abl are non-receptor tyrosine kinases that 
promote   tumor cell migration. This hallmark of 
malignant cell growth is required for  tumor cell 
invasion and metastasis. However, mechanisms by 
which Src and Abl  augment these events are not well 
defined. In this report [1], Khusial et al.  have elegantly 
shown that Src activates Abl, which stabilizes the 
Robo1   receptor to enhance tumor cell migration. 
Robo1 signaling has been  implicated in tumor 
progression and is an enticing target for 
 chemotherapeutic drugs. Robo1, upon binding to its 
ligand Slit2, recruits a  number of Kinases, GTPase 
activating proteins, and Rho GTPases to rearrange  the 
actin cytoskeleton and promote cell migration. The 
authors have demonstrated that Src activates Abl, and 
that Abl associates with Robo1 to  stabilize its activity 
and expression in transformed cells. Importantly, the 
 authors have also shown that siRNA and Kinase 
blockers can reduce Abl  expression and activity to 
dampen Robo1 activity and transformed cell 
 migration. Moreover, they demonstrate that siRNA 
and a monoclonal antibody  against Robo1 (R5 Ab) can 
suppress the migration of transformed cells in the  face 
of robust Src and Abl kinase activity. These studies 
suggest that a variety of reagents may be used to target 
a pathway at different steps to  suppress tumor cell 
migration. 
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